clinical trial · NCT02141438
Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer
Bayer·—·completed·n = 1,472
Metastatic Castration-resistant Prostate CancerRadium-223 dichloride (Xofigo, BAY88-8223)
brief summary
Observational study in the routine clinical practice setting to evaluate the short and long term safety profile of Radium-223 in metastatic castration resistant prostate cancer patients and to evaluate the risk of developing second primary cancers.
started
Aug 20, 2014
primary completion
Aug 2, 2024
completion
Oct 24, 2024
last updated
Oct 16, 2025
official title
Radium-223 Alpha Emitter Agent in Non-intervention Safety Study in mCRPC popUlation for Long-teRm Evaluation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol